Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328020 | 0.89 | MTOR (0.47) | MTORPIK3C3PIK3CDPIK3CA | |
| SCHEMBL23344658 | 0.86 | MTOR (0.44) | MTORPIK3C3ATRATRIPPIK3CD | |
| SCHEMBL23344776 | 0.86 | MTOR (0.44) | MTORPIK3C3ATRATRIPPIK3CD | |
| SCHEMBL18412821 | 0.79 | MTOR (0.47) | MTORPIK3C3ATRATRIPPIK3CD | |
| SCHEMBL15734545 | 0.79 | KMT2A (0.55) | MTORPIK3C3ATR | |
| SCHEMBL25285572 | 0.78 | MTOR (0.53) | MTORATRATRIPPIK3CA | |
| SCHEMBL30454261 | 0.78 | MTOR (0.53) | MTORATRATRIPPIK3CA | |
| SCHEMBL25353363 | 0.78 | MTOR (0.53) | MTORATRATRIPPIK3CA | |
| SCHEMBL25353367 | 0.78 | MTOR (0.53) | MTORATRATRIPPIK3CA | |
| SCHEMBL30455141 | 0.78 | MTOR (0.53) | MTORATRATRIPPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | MTOR 3556/4885PIK3C3 4196/4885ATR 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.